Celldex Therapeutics (CLDX) Cash from Financing Activities (2010 - 2026)

Celldex Therapeutics' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at $327000.0 for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 61.88% year-over-year to $327000.0; the TTM figure through Mar 2026 stood at $2.5 million (down 54.63% YoY), while the FY2025 annual figure was $2.4 million, down 99.46% from the prior year.
• Cash from Financing Activities was $327000.0 for Q1 2026 at Celldex Therapeutics, down from $1.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $436.1 million in Q1 2024 to a low of $63000.0 in Q2 2025.
• Historically, Cash from Financing Activities has averaged $39.2 million across 5 years, with a median of $694000.0 in 2023.
• The sharpest annual moves came in 2024 and 2025: Cash from Financing Activities surged 62740.35% in 2024, then sank 99.95% in 2025.
• A 5-year view of Cash from Financing Activities shows it stood at $1.4 million in 2022, then surged by 15482.37% to $217.4 million in 2023, then tumbled by 99.82% to $386000.0 in 2024, then soared by 249.48% to $1.3 million in 2025, then tumbled by 75.76% to $327000.0 in 2026.
• The last three Cash from Financing Activities figures came in at $327000.0 (Q1 2026), $1.3 million (Q4 2025), and $774000.0 (Q3 2025), per Business Quant data.